9. Questcor Pharmaceuticals (QCOR) has surged 220% in 2010. The Union City, Calif.-based company has grown 12-month sales 25%. Its drug Acthar, used to treat multiple sclerosis, saw a 129% jump in quarterly paid prescriptions.
12-Month Sales Growth: 25%
12-Month Net Income Growth: 7.6%
Cash Flow Multiple: 19 (68% peer premium)
Quarterly Operating Profit Margin: 54%
Analyst Opinions: Just three researchers follow Questcor, with two rating its stock "buy" and one ranking it "hold." Oppenheimer forecasts that the stock will advance 24% to $19. The shares certainly have technical momentum. They've appreciated 44% in the past three months. Acthar was recently approved by the FDA as a safe treatment for infantile spasms, expanding the drug's revenue potential. It is now approved to treat more than 29 disorders.